MEIP May 2024 4.000 put
| Previous close | 1.5000 |
| Open | 1.5000 |
| Bid | 0.0000 |
| Ask | 3.4000 |
| Strike | 4.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.5000 - 1.6600 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
Business WireMEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
SAN DIEGO, May 09, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events.
- Business Wire
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
SAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that the Company’s Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study. Additionall
- Business Wire
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
SAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that 25% of evaluable patients with relapsed metastatic colorectal cancer ("mCRC") in Cohort 1 of the ongoing Phase 1b study evaluating ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation ("OXPHOS"), in combination with bevacizumab (Avastin®) had
